A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized con

详细信息    查看全文

• 作者：Mark A Hull (1)
  Anna C Sandell (2)
  Alan A Montgomery (2)
  Richard FA Logan (3)
  Gayle M Clifford (4)
  Colin J Rees (4)
  Paul M Loadman (5)
  Diane Whitham (2)
  
• 关键词：Aspirin ; Colorectal adenoma ; Colorectal cancer ; Eicosapentaenoic acid ; Omega ; 3 polyunsaturated fatty acid
• 刊名：Trials
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：14
• 期：1
• 全文大小：499KB
• 参考文献：1. Boursi B, Arber N: Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention. / Curr Pharm Des 2007, 13:2274-282. CrossRef
  2. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, Parkin DM, Wardle J, Duffy SW, Cuzick J, UK Flexible Sigmoidoscopy Trial Investigators: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. / Lancet 2010, 375:1624-633. CrossRef
  3. Zauber AG, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD: Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. / N Engl J Med 2012, 366:687-96. CrossRef
  4. Brenner H, Chang-Claude J, Seiler CM, Hoffmeister M: Interval cancers after negative colonoscopy: population-based case–control study. / Gut 2012, 61:1576-582. CrossRef
  5. Hassan C, Rex DK, Cooper GS, Zullo A, Launois R, Benamouzig R: Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis. / Gut 2012, 61:1172-179. CrossRef
  6. Hull MA: Nutritional agents with anti-inflammatory properties in chemoprevention of colorectal neoplasia. / Recent Results Cancer Res 2012, 191:143-56. CrossRef
  7. Chan AT, Arber N, Burn J, Chia W-K, Elwood P, Hull MA, Logan RF, Rothwell PM, Schr?r K, Baron JA: Aspirin in the chemoprevention of colorectal neoplasia: an overview. / Cancer Prev Res 2011, 5:164-78. CrossRef
  8. Zhou P, Cheng SW, Yang R, Wang B, Liu J: Combination chemoprevention: future direction of colorectal cancer prevention. / Eur J Cancer Prev 2012, 21:231-40. CrossRef
  9. Lavie C, Milani R, Mehra M, Ventura HO: Omega-3 polyunsaturated fatty acids and cardiovascular diseases. / J Am Coll Cardiol 2009, 54:585-94. CrossRef
  10. Hull MA: Omega-3 polyunsaturated fatty acids. / Best Pract Res Clin Gastroenterol 2011, 25:547-54. CrossRef
  11. Cockbain AJ, Toogood GJ, Hull MA: Omega-3 polyunsaturated fatty acids for the prevention and treatment of colorectal cancer. / Gut 2012, 61:135-49. CrossRef
  12. Murff HJ, Shrubsole MJ, Cai Q, Smalley WE, Dai Q, Milne GL, Ness RM, Zheng W: Dietary intake of PUFAs and colorectal polyp risk. / Am J Clin Nutr 2012, 95:703-12. CrossRef
  13. Lawson L, Hughes B: Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. / Biochem Biophys Res Comm 1988, 152:328-35. CrossRef
  14. Fini L, Piazzi G, Ceccarelli C, Daoud Y, Belluzzi A, Munarini A, Graziani G, Fogliano V, Selgrad M, Garcia M, Gasbarrini A, Genta RM, Boland CR, Ricciardiello L: Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in ApcMin/+ Mice. / Clin Cancer Res 2010, 16:5703-711. CrossRef
  15. West NJ, Clark SK, Phillips RKS, Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA: Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. / Gut 2010, 59:918-25. CrossRef
  16. Steinbach G, Lynch P, Phillips R, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. / N Engl J Med 2000, 342:1946-952. CrossRef
  17. Arber N, Levin B: Chemoprevention of colorectal neoplasia: the potential for personalized medicine. / Gastroenterology 2008, 134:1224-237. CrossRef
  18. Smith W: Cyclooxygenases, peroxide tone and the allure of fish oil. / Curr Opin Cell Biol 2005, 17:174-82. CrossRef
  19. Greene ER, Huang S, Serhan CN, Panigrahy D: Regulation of inflammation in cancer by eicosanoids. / Prostaglandins Other Lipid Mediat 2011, 96:27-6. CrossRef
  20. Larson MK, Ashmore JH, Harris KA, Vogelaar JL, Pottala JV, Sprehe M, Harris WS: Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. / Thromb Haemost 2008, 100:634-41.
  21. Block RC, Kakinami L, Jonovich M, Antonetti I, Lawrence P, Meedhu N, Calderon Artero P, Mousa SA, Brenna JT, Georas S: The combination of EPA-?DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy volunteers. / Prostaglandins Leukot Essent Fatty Acids 2012, 87:143-51. CrossRef
  22. Cole B, Logan R, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA: Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. / JNCI 2009, 101:256-66. CrossRef
  23. Cairns SR, Scholefield JH, Steele RJC, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR: Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). / Gut 2010, 59:666-90. CrossRef
  24. Bensen S, Mott L, Dain B, Rothstein R, Baron J: The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. / Am J Gastroenterol 1999, 94:194-99. CrossRef
  25. NHS Bowel Cancer Screening Programme: / Quality Assurance Guidelines for Colonoscopy. 6th edition. UK: NHS BCSP Publication; 2011.
  26. Brouwer I, Zock P, Wever E, Hauer RN, Camm AJ, B?cker D, Otto-Terlouw P, Katan MB, Schouten EG: Rationale and design of a randomised controlled trial on supplemental intake of n-3 fatty acids and incidence of cardiac arrhythmia: SOFA. / Eur J Clin Nutr 2003, 57:1323-330. CrossRef
  27. Farmer A, Montori V, Dinneen D, Clar C: Fish oil in people with type 2 diabetes mellitus (Cochrane Review). / Cochrane Database Syst Rev 2001., 3: CD003205
  28. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ: Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. / Am J Clin Nutr 2002, 76:1007-015.
  29. McAlister F, Straus S, Sackett D, Altman DG: Analysis and reporting of factorial trials. / JAMA 2003, 289:2545-553. CrossRef
  
• 作者单位：Mark A Hull (1)
  Anna C Sandell (2)
  Alan A Montgomery (2)
  Richard FA Logan (3)
  Gayle M Clifford (4)
  Colin J Rees (4)
  Paul M Loadman (5)
  Diane Whitham (2)
  
  1. Leeds Institute of Biomedical & Clinical Sciences, St James’s University Hospital, Leeds, LS9 7TF, UK
  2. Queens Medical Centre, Nottingham Clinical Trials Unit, C Floor South Block, Nottingham, NG7 2UH, UK
  3. Nottingham Digestive Diseases Centre, Queen’s Medical Centre, University of Nottingham, Nottingham, NG7 2UH, UK
  4. South Tyneside NHS Foundation Trust, South Shields, Tyne and Wear, NE34 0PL, UK
  5. Institute of Cancer Therapeutics, University of Bradford, Bradford, BD7 1DP, UK
  

文摘

Background The naturally-occurring omega (ω)-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid (EPA) reduces colorectal adenoma (polyp) number and size in patients with familial adenomatous polyposis. The safety profile and potential cardiovascular benefits associated with ω-3 PUFAs make EPA a strong candidate for colorectal cancer (CRC) chemoprevention, alone or in combination with aspirin, which itself has recognized anti-CRC activity. Colorectal adenoma number and size are recognized as biomarkers of future CRC risk and are established as surrogate end-points in CRC chemoprevention trials. Design The seAFOod Polyp Prevention Trial is a randomized, double-blind, placebo-controlled, 2?×- factorial ‘efficacy-study, which will determine whether EPA prevents colorectal adenomas, either alone or in combination with aspirin. Participants are 55-3?year-old patients, who have been identified as ‘high risk-(detection of ? small adenomas or ? adenomas with at least one being ?0?mm in diameter) at screening colonoscopy in the English Bowel Cancer Screening Programme (BCSP). Exclusion criteria include the need for more than one repeat endoscopy within the three-month BCSP screening period, malignant change in an adenoma, regular use of aspirin or non-aspirin non-steroidal anti-inflammatory drugs, regular use of fish oil supplements and concomitant warfarin or anti-platelet agent therapy. Patients are randomized to either EPA-free fatty acid 1?g twice daily or identical placebo AND aspirin 300?mg once daily or identical placebo, for approximately 12?months. The primary end-point is the number of participants with one or more adenomas detected at routine one-year BCSP surveillance colonoscopy. Secondary end-points include the number of adenomas (total and ‘advanced- per patient, the location (left versus right colon) of colorectal adenomas and the number of participants re-classified as ‘intermediate risk-for future surveillance. Exploratory end-points include levels of bioactive lipid mediators such as ω-3 PUFAs, resolvin E1 and PGE-M in plasma, urine, erythrocytes and rectal mucosa in order to gain insights into the mechanism(s) of action of EPA and aspirin, alone and in combination, as well as to discover predictive biomarkers of chemopreventive efficacy. The recruitment target is 904 patients. Trial Registration Current Controlled Trials ISRCTN05926847